Evidence map›Paper›PMID 40488753›Full record

ArticleAnnals of hematology2025

Refinement of intermediate-risk Karyotypes according to the IPSS-R in patients with myelodysplastic neoplasms (MDS).

K Nachtkamp, F Schulz, A Kasprzak, C Strupp, B Hildebrandt, M Pfeilstöcker, P Valent, B Blum, A Giagounidis, K Götze and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

K NachtkampDepartment of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Duesseldorf, Germany. kathrin.nachtkamp@med.uni-duesseldorf.de.ORCID http://orcid.org/0000-0001-5893-2298
F SchulzDepartment of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Duesseldorf, Germany.
A KasprzakDepartment of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Duesseldorf, Germany.
C StruppDepartment of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Duesseldorf, Germany.
B HildebrandtInstitute of Human Genetics, Heinrich Heine University, Duesseldorf, Germany.
M PfeilstöckerMedical Department for Hematology and Oncology, Hanusch Hospital, Vienna, Austria.
P ValentDepartment of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
B BlumService d'hématologie, Département d'oncologie, Centre Hospitalier Universitaire Vaudois, and Lausanne University (UNIL), Lausanne, Switzerland.
A GiagounidisDepartment of Hematology, Oncology and Palliative Care, Marien Hospital, Duesseldorf, Germany.
K GötzeDepartment of Hematology and Oncology, Klinikum Rechts der Isar, Technische Universität Muenchen, Munich, Germany.
V FlattenDepartment of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Duesseldorf, Germany.
S DietrichDepartment of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Duesseldorf, Germany.
G KobbeDepartment of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Duesseldorf, Germany.
D HaaseDepartment of Hematology and Medical Oncology, Georg August University, Göttingen, Germany.
N GattermannDepartment of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Duesseldorf, Germany.
U GermingDepartment of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Duesseldorf, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MDS patients show a heterogenous prognosis which can be stratified by the IPSS-R in order to derive therapeutic implications. Based on 618 patients with myelodysplastic neoplasms belonging to the cytogenetic intermediate-risk group according to IPSS-R, we show that this group is heterogeneous in terms of overall survival and cumulative risk of AML. The group can be reorganized into subgroups according to their prognostic impact. A small subgroup of patients with isolated -X or der(1;7) can be regarded as very-low-risk patients with a median survival time of 112 months and a cumulative AML progression rate of 9% after 2 years. A larger group of patients with either diverse aberrations of one chromosome or -Y + one additional aberration shows a benign course of the disease with a median survival time of 46 months and a cumulative AML progression rate of 26% after 2 years. A very large group of patients presenting with either + 8, +19, i(17q), + 21, +mar, del(9q), + 8 plus one other aberration, or del(7q) have a poor prognosis with a median survival time of 26 months and a cumulative AML progression rate of 32% after 2 years. In a very small set of patients with trisomy 11 the course of disease was similar to very-high-risk patients with a median survival time of 17 months only and a cumulative AML progression rate of 100% after 2 years. These findings could lead to a refinement of prognostic scoring systems such as the IPSS-R and the IPSS-M.

Indexed as

Myelodysplastic SyndromesAdultAgedAged, 80 and overChromosome AberrationsDisease ProgressionFemaleHumansKaryotypeKaryotypingLeukemia, Myeloid, AcuteMaleMiddle AgedPrognosisRisk FactorsSurvival RateIntermediate-riskIPSS-RMyelodysplastic neoplasmsNew karyotype risk groupsPrognosis

Identifiers

PMID40488753
PMCPMC12283795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.